In vivo, we first demonstrated a CD44v6-dependent tumour uptake for AbD15179, with a markedly higher tumour uptake of 125I-Fab in high-CD44v6-expressing tumours compared to the CD44v6-negative tumours, establishing the specificity of the conjugate also in vivo. This evidence concerns the gene FANCB and neoplasm.